Table 2 Cycle characteristics and outcomes
From: Degenerated oocyte in the cohort adversely affects IVF outcome
Characteristic | Non DEG group (n = 318) | DEG group (n = 81) | P-value |
|---|---|---|---|
Estradiol on hCG trigger day (pgr/dl) | 1638 ± 798 | 1990 ± 1304 | 0.002 |
Progesterone level at hCG trigger day | 0.67 ± 0.45 | 0.74 ± 0.47 | NS |
Endometrium (mm) | 9.7 ± 2.3 | 9.6 ± 2.2 | NS |
Duration of treatment (days) | 9.9 ± 2.6 | 10.5 ± 2.6 | NS |
Protocol Number/total cycles (%) | |||
Long Protocol | 51 (16.2) | 21 (27.6) | 0.03 |
Flare/Short agonist | 26 (8.3) | 11 (14.5) | NS |
Antagonist | 233 (74) | 44 (57.9) | 0.007 |
Modified natural cycle | 4 (1.3%) | 0 | NS |
Treatment outcome | |||
Number of Oocyte collected | 10.1 ± 6.1 | 12.9 ± 7.2 | P < 0.001 |
M2 | 7.3 ± 4.4 | 8.4 ± 4.9 | P = 0.063 |
2PN | 5.8 ± 3.8 | 6.2 ± 3.9 | NS |
KID | 3.4 ± 1.6 | 3.2 ± 1.6 | P = 0.002 |
ESHRE | 1.5 ± 1.1 | 1.4 ± 1.0 | P = 0.046 |
KID =4 + 5 (Top quality embryo) | 1174 (58.8%) | 314 (53.0%) | P = 0.012 |
ESHRE 2 + 3 (Top quality embryo) | 1041 (52.2%) | 282 (47.6%) | P = 0.049 |
TOP quality embryo (combined score of- 5,3/5,2/4,3/4,2) | 965/1995 (48.4%) | 257/593 (43.3%) | P = 0.031 |
Chemical pregnancy/cycle | 105/318 (38.5%) | 32 (39.5%) | NS |
Clinical pregnancy/cycle | 105/318 (38.5%) | 29 (35.8%) | NS |